Medicure Inc (TSE:MPH)
:MPH
Want to see TSE:MPH full AI Analyst Report?
MPH Stock Chart & Stats
C$1.25
C$0.01(1.22%)
At close: 4:00 PM EST
C$1.25
C$0.01(1.22%)
Day’s Range― - ―
52-Week RangeC$0.85 - C$1.43
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.72K
Market Cap
C$10.85M
Enterprise ValueC$10.85M
Total Cash (Recent Filing)C$1.54M
Total Debt (Recent Filing)C$803.00K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding10,436,313
10 Day Avg. Volume717
30 Day Avg. Volume1,717
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-21.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA very low debt load and minimal total debt materially reduce near-term refinancing and interest-rate risk. This conservative capital structure preserves strategic optionality for funding R&D or commercialization, and lowers bankruptcy risk while the company works to restore profitability.
Specialty Cardiovascular FocusA focused specialty-pharma franchise in cardiovascular therapies benefits from durable, chronic demand, specialized commercial channels and higher barriers to entry versus commodity generics. This niche positioning supports pricing power and partner interest over the medium term.
Top-line MomentumConsistent revenue growth indicates product traction and improving commercial execution. Sustained top-line expansion can underpin eventual margin recovery and better cash generation if the company stabilizes cost structure and leverages fixed selling infrastructure.
Bears Say
Negative ProfitabilityMaterial net losses are eroding shareholder value and limit reinvestment capacity. Persistent negative profitability forces dependence on cash reserves or external financing, constraining long-term R&D, commercialization scale-up, and strategic flexibility if not reversed.
Sharp Margin CompressionA rapid, multi-year decline in gross margin signals structural pressure—pricing, higher COGS, or unfavorable mix—that reduces the firm’s ability to convert sales into operating profits. Without durable margin recovery, higher sales alone may not generate healthy cash flow.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow creates funding risk and may necessitate dilutive financing or cutbacks to commercialization and development. Poor cash conversion undermines the company’s ability to self-fund growth and increases reliance on external capital markets.
Medicure News
MPH FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was C$0.85 and its highest was C$1.43 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is C$10.85M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Aug 26, 2026 which is in 76 days.
How were Medicure Inc’s earnings last quarter?
Currently, no data Available
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in TSE:MPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicure Inc
Medicure Inc. is a biopharmaceutical firm focused on developing, researching, and commercializing therapeutic solutions for cardiovascular conditions across Canada and the United States. Its product portfolio includes AGGRASTAT, an injectable glycoprotein GP IIb/IIIa receptor antagonist prescribed for acute coronary syndromes, such as unstable angina and non-Q-wave myocardial infarction. The company also provides ZYPITAMAG, a medication used to manage primary hyperlipidemia and mixed dyslipidemia. Additionally, Medicure offers the ReDS system, a non-invasive medical device designed to measure lung fluid levels, aiding in the management of congestive heart failure. Another key offering is Sodium Nitroprusside injection, utilized for rapidly lowering blood pressure during hypertensive crises in both adult and pediatric patients, inducing controlled hypotension for surgical bleeding reduction, and treating acute congestive heart failure. These products are made available through both retail pharmacy networks and online platforms. Established in 1997, Medicure Inc. is headquartered in Winnipeg, Canada.
Technical Analysis
Aequus Pharmaceuticals
―
Pharmadrug
―
Mountain Valley MD
―
Medexus Pharmaceuticals Inc
―
Xebra Brands Ltd.
―